On August 22, 2016, Tiger X Medical, Inc., wholly-owned subsidiary of BioCardia, Inc., Icicle Acquisition Corp., or the Acquisition Sub, BioCardia, Inc., Jay Moyes, as representative of BioCardia's stockholders and option holders, and Steven Rubin, as the initial representative of the Company, entered into an Agreement and Plan of Merger, as subsequently amended on October 21, 2016, or the Merger Agreement. The Merger Agreement closed on October 24, 2016, or the Effective Time, pursuant to which Acquisition Sub merged with and into BioCardia, with BioCardia continuing as the surviving company, or the Merger, under the name BioCardia Lifesciences, Inc. Following the completion of the Merger, changed the name of Tiger X Medical, Inc. to BioCardia, Inc. board of directors is authorized to consist of, and currently consists of, eight members. As of the Effective Time, Steven Rubin, Stephen Liu and Subbarao Uppaluri, directors before the Merger, resigned from their positions as directors.

As of the Effective Time, Peter Altman Ph.D., Jay Moyes, Thomas Quertermous, Simon Stertzer and Allan Tessler, BioCardia's directors before the Merger, as well as Fernando L. Fernandez, Richard Krasno and Richard C. Pfenniger Jr., were appointed to board of directors. Also as of the Effective Time, Steven Rubin, Interim Chief Executive Officer and Interim Chief Financial Officer, and principal executive, secretary, and financial and accounting officer for SEC reporting purposes before the Merger, resigned from these positions, and Peter Altman Ph.D. was appointed as Chief Executive Officer and President, David McClung was appointed as Vice President of Finance and Phil Pesta was appointed as Vice President of Operations by board of directors. Peter Altman Ph.D. will be principal executive officer and David McClung will be principal financial and accounting officer for SEC reporting purposes.